Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
AbbVie submits sNDA for Imbruvica in pediatric indication (NYSE:ABBV)
02:29pm, Monday, 28'th Feb 2022 Seeking Alpha
AbbVie (ABBV) has submitted a supplemental New Drug Application (sNDA) for Imbruvica (ibrutinib) to the FDA as a second-line therapy for chronic graft versus host disease in children.
AbbVie Inc. (ABBV) Seeks New Indication for IMBRUVICA® (ibrutinib) in Pediatric Patients
02:22pm, Monday, 28'th Feb 2022 Marijuana Stocks
AbbVie Seeks New Indication for IMBRUVICA® (ibrutinib) in Pediatric Patients with Chronic…
Investing Club: We''re capitalizing on one of our drug stocks'' incredible run, selling some shares
02:03pm, Monday, 28'th Feb 2022 CNBC
We are locking in more profits in AbbVie on Monday morning following the stock''s impressive run of outperformance recently.
Monday''s top analyst upgrades and downgrades included AbbVie, Alcoa, Alibaba, Best Buy, Beyond Meat, Block, Coinbase Global, Foot Locker, GoPro, Home Depot, Lithium Americas, Nvidia, TotalEnergies, Under Armour, Virgin Galactic, VMware, Zscaler.
AbbVie Seeks New Indication for IMBRUVICA® (ibrutinib) in Pediatric Patients with Chronic Graft Versus Host Disease (cGVHD)
01:00pm, Monday, 28'th Feb 2022 PR Newswire
NORTH CHICAGO, Ill., Feb. 28, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV), today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for IMBRUVICA® (ibrutinib) for the treatment of pediatric and adolescent patients one year…
If You Invested $25,000 in AbbVie In 2013, This Is How Much You Would Have Today
11:15am, Sunday, 27'th Feb 2022 The Motley Fool
The company spun off from healthcare giant Abbott Laboratories nearly a decade ago.
Thinking about trading options or stock in Advanced Micro Devices, Exxon Mobil, Dell Technologies, General Dynamics, or AbbVie?
03:55pm, Friday, 25'th Feb 2022 Benzinga
NEW YORK , Feb. 25, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, XOM, DELL, GD, and ABBV. … Full story available on Benzinga.com
Insights on the Regenerative Medicine Global Market to 2027 - by Type, Application, End-user and Region - ResearchAndMarkets.com
02:38pm, Friday, 25'th Feb 2022 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Regenerative Medicine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com''s offering. The global regenerative medicine market reached a value of US$ 14.78 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 50.44 Billion by 2027, exhibiting a CAGR of 22.6% during 2022-2027. Companies Mentioned Allergan PLC (AbbVie Inc.) Amgen Inc. Baxter International In
Androgen Replacement Therapy Market Is Booming Worldwide 2022-2028 | AbbVie, Inc., Bayer AG, Endo Pharmaceuticals, Plc., Eli Lilly and Company
10:32am, Friday, 25'th Feb 2022 OpenPR
Coherent Market Insights published a business research report on Androgen Replacement Therapy Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2022-2028. Androgen Replacement Therapy Market with 150+ market data Tables, Pie Chat, Graphs & Figures spread through Pages
AbbVie''s Rinvoq demonstrates efficacy in second late-stage Crohn''s study (NYSE:ABBV)
03:59pm, Thursday, 24'th Feb 2022 Seeking Alpha
AbbVie (ABBV) Rinvoq (upadacitinib) met its primary endpoint of clinical remission and endoscopic response at week 12 in a late-stage study in moderate to severe Crohn''s…
AbbVie seeks FDA approval for fourth indication of cariprazine
01:50pm, Tuesday, 22'nd Feb 2022 Seeking Alpha
AbbVie (ABBV) announced Tuesday it submitted a supplemental New Drug Application (sNDA) for the antipsychotic medication cariprazine to the U.S
AbbVie submits Vraylar sNDA for adjunctive treatment of depression
01:47pm, Tuesday, 22'nd Feb 2022 Seeking Alpha
AbbVie (ABBV) has submitted a supplemental New Drug Application to the FDA for approval of Vraylar (cariprazine) as an adjunctive treatment for major depressive disorder.
This Number Is a Big Green Flag for AbbVie Stock
03:53pm, Saturday, 19'th Feb 2022 The Motley Fool
Skyrizi is finally starting to show its revenue potential.
AbbVie Snags FDA Approval for Another Indication. Will It Become Another Blockbuster?
01:38pm, Friday, 18'th Feb 2022 The Motley Fool
Immunology drug Skyrizi was authorized by the Food and Drug Administration to treat psoriatic arthritis.
AbbVie Inc. declares $1.41 dividend (NYSE:ABBV)
04:58pm, Thursday, 17'th Feb 2022 Seeking Alpha
AbbVie (NYSE:ABBV) declares $1.41/share quarterly dividend, in line with previous.Forward yield 3.89%Payable May 16; for shareholders of record April 15; ex-div April 14.See ABBV Dividend…
